子中子捕获疗法作为一种用于冠状肉瘤的新方法:瘤减少和长期控制的案例研究
Junqiang Hong1, Yuan-Hao Liu1,2,3,4,5, Xiaohua Zhu6
1Xiamen Humanity Hospital, Xiamen, Fujian, People's Republic of China.
Advances in radiation oncology
|October 27, 2025
概括
这项研究详细介绍了中子捕获疗法 (BNCT) 首次用于中介质软骨瘤 (MCS),这是一种罕见且耐治疗的癌症. BNCT显示显著的瘤减少和积极的临床反应与可管理的副作用.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- 介质性软骨肉瘤 (MCS) 是一种罕见的软骨形成组织的恶性瘤.
- 对于传统的治疗方法来说,MCS表现出耐药性.
- 需要新的治疗策略来管理这种具有挑战性的恶性瘤.
研究的目的:
- 报告中子捕获疗法 (BNCT) 治疗软骨肉瘤的首次记录应用.
- 为了评估BNCT在患有间膜性软骨肉瘤的患者中的疗效和安全性.
- 探索BNCT作为治疗耐药性软骨髓瘤的潜在替代方案.
主要方法:
- 该患者使用NeuPex AB-BNCT系统和NBB-001 (甲氨酸) 接受了2次BNCT治疗.
- 治疗规划使用了NeuMANTA系统,使用18F-基氨PET-CT作为指导和MRI进行评估.
- 瘤反应被评估使用响应评估标准在固体瘤 (RECIST) 版本1.1.
主要成果:
- 通过BNCT,最大瘤尺寸减少了45.8%,这表明部分反应.
- 患者经历了良好的临床结果,没有严重的不良反应.
- 副作用主要是轻微的 (1-2级),暂时的3级粘膜炎得到了支持性治疗.
结论:
- 子中子捕获疗法显示出作为中介质软骨肉瘤治疗方式的显著潜力.
- BNCT为抗常规疗法的冠状肉瘤病例提供了一个有前途的选择.
- 进一步的研究对于优化MCS和其他难以治疗的癌症的BNCT协议至关重要.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K